The weakness in the oil market has caused this stock and many others to suffer.» Read More
As the market retracts from an all-time high, CNBC Pro used a proprietary method to scan for ETFs that could move higher. Here they are.
Jim Cramer gives his take at lightning speed on caller favorite stocks.
“Mad Money” host Jim Cramer shares his top biotech to cure your portfolio.
"Mad Money" host Jim Cramer shares his top biotech to cure your portfolio.
Dr. Randall Schatzman, Adler Biopharmaceuticals Inc. co-founder, president and CEO, discusses the success of its migraine treatment, with Mad Money's Jim Cramer.
Mad Money's Jim Cramer looks a potential merger between T-Mobile and Dish Network.
"The market seems fraught at the moment," says Mad Money host Jim Cramer who outlines headwinds for tomorrow's trade.
Jim Cramer speaks with Carnival's CEO about how he managed to pull off the most impressive turnaround in history.
Jim Cramer wants to know, how do you deny a rumor that makes so much sense?
Jim Cramer wants investors to be prepared for three big, bad events on Friday that could determine the direction of the market.
The Fast Money traders share their final trades of the day.
Discussing mergers and acquisitions in the media space, with Walter Piecyk, BTIG.
Raoul Pal, Global Macro Investor publisher, outlines reasons why we may be on the brink of a recession in the U.S.
Ken Sena. Evercore ISI, puts a hold on Twitter's stock but says Facebook is a buy.
Biotech's health breakthroughs. CNBC's Meg Tirrell cholesterol drugs in the pipeline.
CNBC's Sue Herera reports on the scale and scope of a massive data breach against the U.S. government.
What to expect from OPEC's meeting in Vienna, with Helima Croft, RBC chief commodities strategist.
According to the Dow Jones the probes are part of SEC scrutiny of investor disclosures, reports CNBC's Kate Kelly.
Dissecting the day's market action, with the Fast Money traders.
The "Fast Money" traders give you 4 trades in financials.